Literature DB >> 24646903

Therapeutic use of mini-scleral lenses in a patient with Graves' ophthalmopathy.

Jennifer S Harthan1.   

Abstract

Patients with Graves' ophthalmopathy can be very challenging to manage secondary to the complex nature of their disease presentation. Patients may present with a variety of ocular findings including: lid retraction, periorbital and lid swelling, chemosis, conjunctival hyperemia, proptosis, optic neuropathy, restrictive myopathy, exposure keratopathy and/or keratoconjunctivitis sicca. Mini-scleral and scleral lens designs have been important in the management of irregular and regular corneas, and in the therapy of ocular surface diseases. We present here the case of a 48-year-old Caucasian male who had been diagnosed with Graves' ophthalmopathy 13 years earlier. With significant ocular surface staining and over ten diopters of astigmatism, the patient had never been able to wear contact lenses comfortably. After being fit with the Mini-Scleral Design™ lenses, his vision improved to 20/25 OU, his ocular surface improved, and overall quality of vision increased.
Copyright © 2012 Spanish General Council of Optometry. Published by Elsevier Espana. All rights reserved.

Entities:  

Keywords:  Enfermedad de la superficie ocular; Graves’ Ophthalmopathy; Lentes de contacto mini esclerales; Mini-scleral contact lenses; Ocular surface disease; Oftalmopatía de Graves

Mesh:

Year:  2013        PMID: 24646903      PMCID: PMC3938744          DOI: 10.1016/j.optom.2012.11.002

Source DB:  PubMed          Journal:  J Optom        ISSN: 1989-1342


  13 in total

1.  Scleral contact lenses for overnight wear in the management of ocular surface disorders.

Authors:  M J Tappin; K W Pullum; R J Buckley
Journal:  Eye (Lond)       Date:  2001-04       Impact factor: 3.775

2.  Scleral contact lenses: the expanding role.

Authors:  Kenneth W Pullum; Mark A Whiting; Roger J Buckley
Journal:  Cornea       Date:  2005-04       Impact factor: 2.651

3.  Role of mini-scleral gas-permeable lenses in the treatment of corneal disorders.

Authors:  Ping Ye; Amy Sun; Barry A Weissman
Journal:  Eye Contact Lens       Date:  2007-03       Impact factor: 2.018

4.  Scleral contact lenses may help where other modalities fail.

Authors:  Ori Segal; Yaniv Barkana; Dafna Hourovitz; Shmuel Behrman; Yifaa Kamun; Isaac Avni; David Zadok
Journal:  Cornea       Date:  2003-05       Impact factor: 2.651

Review 5.  Pathogenesis of graves ophthalmopathy: implications for prediction, prevention, and treatment.

Authors:  James A Garrity; Rebecca S Bahn
Journal:  Am J Ophthalmol       Date:  2006-07       Impact factor: 5.258

6.  Scleral contact lenses.

Authors:  J M Cotter; P Rosenthal
Journal:  J Am Optom Assoc       Date:  1998-01

7.  Ocular surface and dry eye in Graves' disease.

Authors:  Canan Gürdal; Ozge Saraç; Ipek Genç; Hale Kırımlıoğlu; Tamer Takmaz; Izzet Can
Journal:  Curr Eye Res       Date:  2011-01       Impact factor: 2.424

8.  Scleral lenses in the management of keratoconus.

Authors:  Muriel M Schornack; Sanjay V Patel
Journal:  Eye Contact Lens       Date:  2010-01       Impact factor: 2.018

Review 9.  Update on scleral lenses.

Authors:  Deborah S Jacobs
Journal:  Curr Opin Ophthalmol       Date:  2008-07       Impact factor: 3.761

Review 10.  Ocular manifestations of autoimmune disease.

Authors:  Sayjal J Patel; Diane C Lundy
Journal:  Am Fam Physician       Date:  2002-09-15       Impact factor: 3.292

View more
  3 in total

1.  A non-surgical approach to the management of exposure keratitis due to facial palsy by using mini-scleral lenses.

Authors:  Victor Zaki
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.889

Review 2.  Therapeutic uses of scleral contact lenses for ocular surface disease: patient selection and special considerations.

Authors:  Jennifer S Harthan; Ellen Shorter
Journal:  Clin Optom (Auckl)       Date:  2018-07-11

Review 3.  Ophthalmic Drug Delivery Systems for Antibiotherapy-A Review.

Authors:  Marion Dubald; Sandrine Bourgeois; Véronique Andrieu; Hatem Fessi
Journal:  Pharmaceutics       Date:  2018-01-13       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.